The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Videos  >  

Overview of Advances in Recent Years for Patients With AML

Daniel A. Pollyea, MD, MS
Published Online:7:02 PM, Wed October 10, 2018


Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses how far the field of acute myeloid leukemia (AML) has come in the last 1 to 2 years.

For years, this patient population had limited treatment options with poor outcomes, according to Pollyea. Over the last few years, there has been a huge acceleration in terms of options available for these patients. 

Pollyea says these advancements are due in part to the years of diligent work in researching, networking, and forming relationships with pharmaceutical colleagues. The treatment landscape for patients with AML has entered a new era where there are a lot of promising options.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.